Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (125)	9/1/2000 8:01:04 AM
From: Jim Oravetz	Read Replies (2) \| Respond to of 164

semi-OT:CALGARY, Alberta--(BUSINESS WIRE)--Sept. 1, 2000--Oncolytics Biotech Inc.(TSE:ONC.) reported today that the U.S. Patent and Trademark Office has issued Patent 6,110,461 to the Company effective August 29, 2000. The patent covers the pharmaceutical use of the reovirus in the treatment of Ras-mediated cancers in mammals. "The issuance of this patent provides us with our initial proprietary position with respect to the development of reovirus as a therapeutic for the treatment of cancer," said Dr. Matt Coffey, Vice President Product Development. "It is exciting and gratifying to receive approval for these broad-based claims. It solidifies our platform by providing intellectual property protection and removes an important element of risk in the development and commercialization process". Jim